Pacific Biosciences of California, Inc.
NASDAQ:PACBMedical - Devices
+$0.04 today
- Market cap
- $571.39M
- Beta
- 2.32
- P/E (TTM)
- -3.3
- EPS (TTM)
- -$0.42
Volume 15.30M
Average 6.06M
PACB EBITDA Margin
EBITDA as a percentage of revenue.
Pacific Biosciences of California, Inc.NASDAQ: PACB
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -15.5%
EBITDA Margin was -15.5% in Q1 FY2026, up 124.1 pp from a year earlier. On a trailing-twelve-month basis it was -66.6%, up 85.7 pp year over year. Over 3 fiscal years it widened by 198.6 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 5 analysts of 121.1% for the fiscal year ending Dec 2026, up from -21.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -15.5%+60.2 pp QoQ
- Last fiscal yearDec 2025
- -21.4%+136.3 pp YoY
- LTMMar 2026
- -66.6%+85.7 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -21.4%
- Year-over-year change
- +136.3pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -21.4% | +136.3pp |
| FY2024 | 2024-12-31 | -157.6% | -22.4pp |
| FY2023 | 2023-12-31 | -135.2% | +84.8pp |
| FY2022 | 2022-12-31 | -220.0% | -27.8pp |
| FY2021 | 2021-12-31 | -192.1% | — |
EBITDA Margin vs competitors
How PACB compares with its peers on the latest reported figures
- PACB's LTM Mar 2026 EBITDA Margin of -66.6% is the 2nd highest of the 3 companies compared; the peer median is -2661.2%.
- Its year-over-year change of +85.7 pp is the highest of 3, against a peer median of -1285.0 pp.
- Over three fiscal years its change of +198.6 pp compares with a peer median of +119.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 30.3% | -11.3 pp | +119.0 pp | |
| LTM Mar 2026 | -66.6% | +85.7 pp | +198.6 pp | |
| LTM Mar 2026 | -5352.8% | -2558.8 pp | — | |
| Peer median (excluding PACB) | -2661.2% | -1285.0 pp | +119.0 pp | |
Competitors are the stored peer set for PACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 130.51M | 128.3M | 200.52M | 154.01M | 160.01M |
| Cost of Revenue | 71.65M | 79.27M | 147.74M | 116.73M | 109.33M |
| Gross Profit | 58.86M | 49.04M | 52.78M | 37.28M | 50.67M |
| Gross Margin | 45.1% | 38.2% | 26.3% | 24.2% | 31.7% |
| Research & Development | 112.9M | 193M | 187.17M | 134.92M | 97.31M |
| Selling, General & Admin | 124.12M | 160.85M | 169.82M | 175.02M | 141.49M |
| Operating Expenses | 269.3M | 356.23M | 387.25M | 511.6M | 608.24M |
| Depreciation & Amortization | 11.59M | 17.32M | 32.69M | 53.35M | 504.91M |
| EBITDA | (250.76M) | (282.24M) | (271.13M) | (242.77M) | (34.2M) |
| EBITDA Margin | -192.1% | -220.0% | -135.2% | -157.6% | -21.4% |
| Operating Income | (210.44M) | (307.2M) | (334.47M) | (474.31M) | (557.56M) |
| Operating Margin | -161.2% | -239.4% | -166.8% | -308.0% | -348.5% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 12.53M | 14.69M | 14.34M | 13.41M | 6.95M |
| Other Income / Expenses | (64.44M) | (7.05M) | 16.31M | 164.78M | 11.5M |
| Income Before Tax | (274.87M) | (314.25M) | (318.16M) | (309.54M) | (546.06M) |
| Pre-Tax Margin | -210.6% | -244.9% | -158.7% | -201.0% | -341.3% |
| Income Tax Expense | (93.65M) | 0 | (11.42M) | 316K | 318K |
| Net Income | (181.22M) | (314.25M) | (306.74M) | (309.85M) | (546.38M) |
| Net Margin | -138.9% | -244.9% | -153.0% | -201.2% | -341.5% |
| EPS (Basic) | (0.89) | (1.40) | (1.21) | (1.13) | (1.82) |
| EPS (Diluted) | (0.89) | (1.40) | (1.21) | (1.07) | (1.82) |
| Weighted Avg Shares | 203.62M | 224.55M | 253.63M | 274.49M | 299.96M |
| Weighted Avg Shares (Diluted) | 204.14M | 224.55M | 253.63M | 288.37M | 299.96M |
Pacific Biosciences of California, Inc.
NASDAQ:PACB
Intrinsic Alpha fair value
Locked
Current Price
$1.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.